H3-DYNAMICS
15.12.2022 14:34:41 CET | Business Wire | Press release
H3 Dynamics and HyLight have joined forces to bring new long range, sustainable and quiet unmanned airships to a range of commercial applications. Traditionally, airships use combustion engines for their propulsion power. With new hydrogen propulsion system developments at H3 Dynamics, HyLight’s new breed of airships will now offer long-range zero emission flight and open a whole new category in air mobility. The two companies share a common goal, to decarbonize the aerial industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221215005555/en/
HyLight’s compact airship is powered by H3 Dynamics hydrogen air-mobility power systems
HyLight and H3 Dynamics started working together several months ago in France, and HyLight have now achieved a first successful hydrogen-electric flight test campaign in Milan, Italy. HyLight is an up and coming french start-up and one of the very few companies in the world that was able to demonstrate hydrogen as a viable power supply for small unmanned airships in real conditions. This was made possible with H3 Dynamics’ aerospace-grade hydrogen fuel cells - the smallest and lightest in the world - have pioneered hydrogen flight research from as early 2006.
HyLight’s unmanned airships move slowly but don’t need to consume any power to stay aloft. They can operate for days at a time with heavier payloads compared to conventional drones, to conduct long range inspection of critical energy assets like power-lines & pipelines or scan industrial infrastructure over long distances. Airships could also hover around specific areas to provide critical connectivity for large scale industrial sites - or provide vital communications after a natural disaster.
Based in Toulouse, H3 Dynamics is set on decarbonizing air mobility with clean hydrogen-electric propulsion, starting with enabling smaller unmanned systems - whether fixed wing, multi-rotor or VTOL platforms. Its ultra-light power technology is bringing new long electric flight durations to the global unmanned aviation market, which is set to reach $38 Billion by 2027.
Earlier this year H3 Dynamics flew the world’s first distributed hydrogen-electric nacelles on a small unmanned platform, proving the potential for larger size systems in bigger aircraft. H3 Dynamics has since become part of the “Toulouse Pioneers” group linked to the Aerospace History Museum “L’Envol des Pionniers”. The company plans to scale its solutions to larger unmanned and manned aviation platforms over the coming years.
HyLight will leverage H3 Dynamics’ international presence covering Europe, North and South America as well as Asia and Australia to bring “made in France” hydrogen-electric airships to the global market.
About HyLight: https://www.hylight.aero
HyLight wants to decarbonize the aerial data industry by providing long-range aerial data collection and analysis services using its unmanned airship systems for the inspection of power lines, pipelines, and railways. Its airship come with hydrogen electric propulsion making them sustainable, silent, efficient, and long-range to cover large areas or distances. The company was started in France and has recently demonstrated the first flight of its hydrogen-electric platform. HyLight was selected to participate in the 1st Batch of the acceleration program of Berkeley SkyDeck Europe, Milano ; the company is also a member of the Hub Drone Systematic and U-LTA and has been financially supported by La Région Grand Est in France.
About H3 Dynamics www.h3dynamics.com
H3 Dynamics is based in Toulouse, Austin and Singapore - and is on a mission to decarbonize aviation with a unique technology solution around distributed hydrogen-electric propulsion, as well as ground refueling solutions. The company’s initial commercial focus is on the scale up of autonomous digital services that link to networks of charging stations for off-the-shelf battery-drones, making way for BVLOS hydrogen UAS capability. H3 Dynamics is a member of the Alliance for Zero Emission Aviation under the European Commission, Sustainable Aero Lab, the Lufthansa Cleantech Hub, the Paris Advanced Air Mobility Alliance, and Aerospace Valley in Toulouse.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005555/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom